Conference programme
Session labelling: K= Keynote – L= Lay – P = Professional.
Location: K= Norðurljós – L= Edition – P = Norðurljós
| Thursday 9 June | ||||
| RIWC 2022 | View NOK 2022 Programme | |||
| Hall | Norðurljós | Björtuloft | Eldborg | |
| 12:00-13:30 | ||||
| 13:30-15:00 | ||||
| 15:00-15:30 | ||||
| 15:30-17:00 | ||||
| 17:30-19:00 | NOK and RIWC OPENING CEREMONY @ ELDBORG HARPA. The President of Iceland, Mr. Guðni Th. Jóhannesson, will open the congress Keynote: Phenotyping and Genotyping in inherited retinal diseases. Prof. Bart Leroy from the University of Ghent, Gent, Belgium Genetics of common diseases, focus on the eye Speaker: Speaker: Hreinn Stefansson, PhD Head of CNS deCODE genetics | |||
| 19:00-20:00 | GET TOGETHER @ HARPA |
| Friday 10 June | |||
| RIWC 2022 | View NOK 2022 Programme | ||
| Hall | Norðurljós (Professional) | The Reykjavik EDITION (Layman) | |
| 07:40-08:20 | |||
| 08:30-10:00 | Age related macular Degeneration Moderator: Dr. Jóhann Ragnar Guðmundsson, Iceland and Teresa Sandhina, England | L.2.1 Retinal degenerations. Clinical aspects. Moderator:Professor dr. Elise Heon, The Hospital for Sick Children, Toronto, Canada | |
| 08:30 - 08:50 The socioeconomic impact of GA and wAMD in Bulgaria, Germany and the United States Speaker: Nabin Paudel, Retinal International | 08:30 – 08:50: Clinical aspects of IRD Speaker: Professor dr. Elise Heon The Hospital for Sick Children, Toronto, Canada | ||
| 08:50 - 09:05 AMD research at Oslo University Hospital: from LUCAS to compounding pharmacy and beyond Speaker: Professor dr. Morten Carstens Moe, Oslo University Hospital, Oslo, Norway | 08:50 - 09:10: Clinical aspects of inherited macular degenerations. Speaker: Associated professor dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark. | ||
| 09:05 - 09:15 Off-label use of Avastin: Scandinavian disparities Speaker: Tomas Bro, MD, PhD, Höglandssjukhuset, Eksjö, Sweden | 09:10 - 09:30 Syndromic forms of IRD. Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France | ||
| 09:15 - 09:25 The risk of extending AMD treatment Speaker:David Epstein, MD, PhD. Sankt Erik Eye Hospital, Karolinska Institute, Stockholm, Sweden | |||
| 09:25 - 09:35 The Swedish Macula Register Speaker: Inger Westborg, MD, PhD. Uppsala University Hospital, Uppsala, Sweden | |||
| 09:35 - 09:50 AMD Epidemiology. Genetics & Associated Serum Proteins. Ocular, Systemic & Lifestyle Risks Speaker: Professor emeritus dr. Friðbert Jónasson, University of Iceland, Iceland | 09:30 - 09:50: The genetic testing landscape Speaker: Fiona Waters, Retina International, Dublin, Ireland | ||
| 09:50 - 10:00 QnA | 09:50 – 10:00 QnA | ||
| 10:00-10:30 | Coffee break | ||
| 10:30-11:30 | P.2.2 Assessment of Endpoints in clinical studies. Moderators: Associate professor dr. Cecilie Bredrup, Bergen, Norway and Professor dr. Sten Kjellström, Lund, Sweden. | L.2.2 Retinal degenerations - the genetics. Moderator: Prof. dr. Jón Jóhannes Jónsson, national University Hospital, Reykjavík, Iceland. | |
| 10:30 – 10:50: Experiences with Luxturna Speaker: Associate professor dr. Line Kessel, Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark | 10:30 – 10:50: Pattern of inheritance - easy to understand. Speaker: Dr. Eirný Þórólfsdóttir National University Hospital, Reykjavík, Iceland. | ||
| 10:50 – 11:10 Paediatric specificities in trials Speaker: Prof. dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada | 10:50 – 11:10: Understanding the results - a difficult task. Speaker: Prof. dr. Jón Johannes Jónsson, national University Hospital, Reykjavík, Iceland. | ||
| 11:10 – 11:30: Developing Patient Relevant Outcomes in Gene Therapy Trials: The Novel Functional Vision Endpoint, the Multi-luminance Mobility Test (MLMT) Speaker: Dr. Daniel Chung, DO, MA, Spark Therapeutics, Philadelphia, USA | 11:10 – 11:20 Lessons from Iceland on the diversity of genetic causes. Speaker: Daníel Þorsteinsson | ||
| 11:20 – 11:30: ABCA4 related IRDs. Speaker: Professor dr. Frans Cremers, Radboud University, Nijmegen, Netherlands | |||
| 11:30-12:00 | K.2.1 Keynote: Stem cell therapy for retinal regenerative diseases Speaker: Dr. Masayo Takahashi, Vision Care Inc., Kobe, Japan Norðurljós Hall | ||
| 12:00-13:30 | Lunch | ||
| 12:15-13:15 | Lunch symposia: Retina International Network of Partners Meeting @ Norðurljós Moderator: Jason Menzo, President and COO, Foundation Fighting Blindness, USA | ||
| 12:15-12:20 | Welcome – Mr. Franz Badura, Chair, Retina International | ||
| 12:20-12:25 | Patient Public Involvement in research life cycle: Concept to Delivery – Ms. Avril Daly, CEO, Retina International | ||
| 12:25-12:40* | Understanding the Economic Burden and Societal impact of AMD/GA - Dr. Nabin Paudel, Research and Innovation Manager, Retina International | ||
| 12:40-12:55* | IRDs - Counting the Cost Understanding the Impact – Ms. Fiona Waters, Education and Engagement Manager, Retina International | ||
| 12:55-13:10* | Challenges of Outcome Measures in Retinal Degeneration – Prof. Dr. Elise Heon The Hospital for Sick Children, Toronto, Canada | ||
| 13:10-13:15 | Closing remarks - Martin Smedstad, Oslo, Norway | ||
| * This session includes 5 minutes for Q&A | |||
| 13:30-14:00 | Keynote: Scientific results, a rollercoaster between hope and deception Speaker: Christina Fasser, former president of the Retina International, Zurich, Switzerland Norðurljós Hall | ||
| 14:00-15:00 | Phenotype-Genotype Correlations in IRD Moderators: Josephine Prener Holtan MD, PhD, Oslo University Hospital, Oslo, Norway, and Professor dr. Bart Leroy, Ghent, Belgium | L.2.3 Basics of stem cell and gene-based therapies. Moderator: Prof. Kapil Bharti. National Eye Institute, Bethesda, USA | |
| 14:00 – 14:10: Natural history and clinical characterization of patients with retinitis pigmentosa caused by mutations in the PRPF31 gene Speaker: Dr. Kristian Lisbjerg, Copenhagen University Hospital, Denmark | 14:00- 14:20 Overview of on-going clinical trials with stem cells Speaker: Prof. dr. Goran Petrovski | ||
| 14:10 – 14:20: Genetic basis and phenotypic characterization of Danish patients with Achromatopsia. Speaker: Dr. Mette K.G. Andersen, Copenhagen University Hospital, Rigshospitalet-Glostrup, Copenhagen, Denmark | 14:20 – 14:35 Stem Cell Based Trials for AMD Speaker: Professor dr. Kapil Bharti. National Eye Institute, Bethesda, USA | ||
| 14:20 – 14:35 Whole exome sequencing in the diagnosis of hereditary retinal disorders: A clinical perspective Speaker: Dr. Ragnhild Wivestad Jansson, Haukeland University Hospital, Norway | 14:35 – 14:50 Clinical trial in opto-genetics. Speaker: Prof. dr. Isabelle Audo, INSERM, Paris, France | ||
| 14:30 – 14:50 ERN-EYE a booster for patients care and research for Rare Eye Diseases in Europe Speaker: prof. Dr. Hélène Dollfus, CARGO, Hôpitaux Universitaires de Strasbourg, France | 14:50 – 15:00 How to identify real treatments and good clinical trials as a patient Speaker: Martin Smedstad, The Retinitis Pigmentosa Association, Oslo, Norway | ||
| 15:00-15:30 | Coffee break | ||
| 15:30-16:00 | Keynote: Restoration of vision Speaker: Professor dr. Mark S. Humayun. University of Southern California, Los Angeles, USA Norðurljós Hall | ||
| 16:00-17:00 | Innovations in Ophthalmology Moderators: Christina Fasser, Retinal International, and Professor dr. Einar Stefánsson. University of Iceland, Iceland | L.2.4 Service and Coping with Low Vision. Moderator: Elfa Svanhildur Hermannsdóttir, National Instuitute for the blind in Iceland | |
| 16:00-16:15 Agnostic gene therapy approaches Speakers: Dr. Daniel Chung, DO, MA, Philadelphia, USA | 16:00 - 16:15: National Institute for the blind and visually impaired in Iceland Speakers: Elva Dögg Jóhannesdóttir Ophthalmologist and Vala Jóna Garðarsdóttir O&M. | ||
| 16:15-16:30 Eye drops with solubilizing nanoparticle technology in the treatment of Diabetic Macular Edema Speaker: Þorsteinn Loftsson. University of Iceland, Oculis SA Reykjavik, Iceland | 16:15 – 16:30 Reading with auxiliary aids Speaker: Rósa María Hjörvar. PhD student in Literature at the University of Iceland | ||
| 16:30-16:45 The RD Fund, Innovation in Venture Philanthropy Speaker: Jason Menzo – President and Chief Operating Officer, Foundation Fighting Blindness USA | 16:30-16:45: The assistive technology, aps etc. Speakers: Baldur Snær Sigurðsson and Hlynur Þór Agnarsson | ||
| 16:45-17:00 Optogenetics: Next generation strategy for advanced retinal diseases Speaker: Kamron Khan, Novartis | 16:45 - 17:00: Coping with visual impairment in live and work Speakers: Halla Dís Hallfreðsdóttir and Elín Yr. Hafdisardóttir Arnardóttir. | ||
| 17:30-18:30 | Zum Geburtstag Prof. Dr. Dr. Einar Stefánsson | ||
| 19:00 | Speakers dinner @ Hilton Reykjavík Nordica - Vox Club |
| Saturday 11 June | |||
| RIWC 2022 | View NOK 2022 Programme | ||
| Hall | Norðurljós (Professional) | The Reykjavik EDITION (Layman) | |
| 08:00-08:30 | |||
| 08:30-10:00 | New Developments in IRD. Moderator: Professor dr. Michael Larsen | L.3.1 Clinical trials and therapies from a patient’s perspective. Moderator: Martin Smedstad, Oslo, Norway. | |
| 08:30-08:50 Accessing Genetic Testing for IRDs: The Patient Perspective. Speaker: Fiona Waters, Retina International, Dublin, Ireland | 08:30 – 08:50 Overview and future on on-going clinical trials Speaker: Professor dr. Elise Heon, MD, The Hospital for Sick Children, Toronto, Canada | ||
| 08:50-09:10 ABCA4 retinal dystrophies Speaker: Professor dr. Frans Cremers, Radboud University, Nijmegen, Netherlands | 08:50 – 09:10 RPE65 - the first gene therapy on the market Speaker: Associate professor dr. Line Kessel, Glostrup, Copenhagen, Denmark | ||
| 09:10-09:30 PERCEIVE study report: Real-world safety and effectiveness of voretigene neparvovec AND Evaluating a new questionnaire to assess symptoms in RP and LCA Speaker: Professor dr. Dominik Fischer, Oxford Eye Hospital, University of Oxford, Oxford, United Kingdom | 09:10 – 09:30 Oligonucleotides - a hope for all? Speaker: Professor dr. Bart Leroy, Gent University, Ghent, Belgium | ||
| 09:30-10:00 Medical therapies in IRD Speaker: Professor dr. Robert Koenekoop, Montreal Childrens Hospital, Montreal, Canada | 09:30 – 09:50 My personal experience of gene therapy Speaker: Camilla Jensen, Oslo, Norway | ||
| 10:00-10:30 | Coffee break | ||
| 10:30-12:00 | Stem cells and cell-based therapies of retinal diseases. Moderator Professor Dr. Goran Petrovski, Oslo, Norway. | L 3.2 Retina International - the global challenges Global Genetic Testing Landscape Moderator: Fiona Waters, Retina International, Ireland | |
| 10:30 - 10:50 Initiating a Phase I/IIa clinical trial for an autologous iPS cell therapy for macular degeneration: from bench-to-bedside Speaker: Dr Kapil Bharti (NIH/NEI), Bethesda, USA | 10:30 – 11:15 Impact of age related retinal diseases on society, and calls to action Speaker: Nabin Paudel, RI, Ireland Panel Discussion – TBC | ||
| 10:50 - 11:10 Towards stem cell-based therapy in retinal degeneration. Speaker: Professor Dr. Anders Kvanta, Stockholm, Sweden | 11:15 – 12:00 Genetic Testing Landscape – a global policy action to support equitable access. Speaker: Avril Daly, Retina International, Ireland Panel Discussion - TBC | ||
| 11:10 – 11:30 Genetically corrected iPS-derived RPE cells for cell therapy of hereditary retinal dystrophy. Speaker: Dr. Slaven Erceg, Valencia, Spain | |||
| 11:30 - 11:50 Subretinal implantation of primary human RPE cells in minipig eyes. Speaker:Professor Dr. Goran Petrovski, Oslo, Norway | |||
| 11:50 - 12:00 Retinal repair by autologous transplantation. Speaker: Docent Dr. Xhevat Lumi | |||
| 12:00-13:00 | Lunch | ||
| 12:30-13:00 | Poster viewing | ||
| 13:00-14:00 | Keynote: Gene based therapies of retinal diseases Speaker: Prof. Artur Cideciyan, University of Pennsylvania, Philadelphia, USA. Norðurljós Hall | ||
| 14:00-15:00 | Gene based therapies of retinal diseasesModerator: Eeva-Marja Sankila, MD, PhD, Helsinki University Hospital, Helsinki, Finland | Programme in islandic for the public. Stjórnandi: Sigþór U. Hallfreðsson, Félag blindra og sjónskertra, Íslandi | |
| 14:00 – 14:15 CPK850 gene therapy in RLPB1 patients. Speaker: Prof. Anders Kantar, Karolinska Institute, Stockholm, Sweden | 14:00-14:20 Hvað er efst á baugi í rannsóknum og meðferð arfgengra sjónhimnusjúkdóma? Speaker: Prófessor dr. Ragnheiður Bragadóttir, Oslo universitetssykehus, Osló, Noregi | ||
| 14:15 – 14:30 Gene therapy of Choroideraemia and X-linked retinitis pigmentosa - Lessons to be learned Speaker: Prof. Professor dr. Robert Koenekoop, Montreal Childrens Hospital, Montreal, Canada | 14:20-14:40 Greining og skráning arfgengra sjónhimnusjúkdóma á Íslandi Speaker: Prófessor dr. Jón Jóhannes Jónsson, Landspítalinn, Reykjavík | ||
| 14:30 – 14:45 Retinal gene therapy in choroideremia patients - surgical aspects. Speaker: Professor dr. Ilkka Immonen, Helsinki University Hospital, Helsinki, Finland. | 14:40-15:00 Hvernig getum við með arfgenga sjónhimnusjúkdóma verið með í rannsóknum? Speaker: Helgi Hjörvar, Félag blindra og sjónskertra, Íslandi | ||
| 14:45 – 15:00 Gene therapy of Usher syndrome. Speaker: Professor dr. Isabelle Audo, Institute de la Vision, Paris, France. | 15:00-15:15 Þjónusta við blinda og sjónskerta á Íslandi: Notendur á Sjónstöð og algengustu orsakir sjónskerðingar. Speaker: Elva Dögg Jóhannesdóttir, Íslandi | ||
| 15:30 | GRAND FINALE AND FUTURE STEPS @ SILFURBERG Looking to the Future: Care for IRD Patients in the Coming 10 Years Speaker: Professor dr. Bart Leroy, University of Ghent, Gent, Belgium Speaker: Professor dr. Einar Stefánsson, University of Iceland, Iceland Introduction of NOK2024 | ||
| 19:00 | Gala Dinner @ Gamla Bíó | ||